OrbiMed’s Revolution Medicines RVMD Stock Holding History

OrbiMed’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.36M	Buy	+50,000	New	+$7.3M	0.17%	85

Other funds holding RVMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

OrbiMed's RVMD Position: Q2 2026 in Review

OrbiMed increased its Revolution Medicines (RVMD) stake by 36% in Q2 2026, buying an estimated $2.7M and bringing the position to 70,500 shares worth $13.2M. The position accounts for 0.24% of the portfolio, ranked #81.

OrbiMed first reported a position in RVMD in Q1 2020 and has held it in 4 quarters since. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

OrbiMed held 70,500 shares of Revolution Medicines worth $13.2M as of Q2 2026.
OrbiMed bought 18,500 Revolution Medicines shares in Q2 2026, an estimated $2.7M.
Revolution Medicines made up 0.24% of OrbiMed's portfolio in Q2 2026, its #81 holding.
OrbiMed first reported a position in Revolution Medicines in Q1 2020 and has held it in 4 quarters since.
690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.